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Abstract
Background: The Pseudomonas aeruginosa major constitutive outer membrane porin protein F (OprF) has been
shown to be a protective antigen and was previously used to activate an immunological response in a mouse
model of lung pneumonia. The purpose of our study was to demonstrate the ability of mouse dendritic cells
pulsed with purified or recombinant OprF to protect mice against P. aeruginosa infection and inflammation.
Both native (n-OprF), isolated and purified from PAO1 bacterial strain, and recombinant (histidin-conjugated) OprF
(His-OprF), obtained by cloning of the oprF gene into the pET28a expression vector, were used to stimulate dendri-
tic cells in vitro before adoptive transfer into prospective recipient mice with P. aeruginosa pulmonary infection.
Results: Similar to n-OprF, His-OprF activated dendritic cells in vitro, inducing the costimulatory molecule
expression as well as cytokine production. Upon adoptive transfer in vivo, porin-pulsed dendritic cells (DCs)
induced Th1-mediated resistance to infection and associated inflammatory pathology caused by either the PAO1
strain or a clinically-isolated mucoid strain.
Conclusions: This study highlights the pivotal contribution of DCs to vaccine-induced protection against P.
aeruginosa infection and associated inflammation.
Background
Pseudomonas aeruginosa, an ubiquitous environmental
Gram-negative microrganism, is one of most important
opportunistic bacteria in hospital-acquired infections
[1-3]. It is responsible for acute and chronic lung infec-
tions in artificially ventilated [4] and in cystic fibrosis
patients [5], and for septicemia in immunocompromised
patients, including transplant and cancer patients, as
well as patients with severe burn wounds. Nosocomial
P. aeruginosa strains are characterized by an intrinsic
resistance to various antimicrobial agents and common
antibiotic therapies. The low permeability of the major
outer membrane porins and the presence of multiple
drug efflux pumps are factors that contribute to
mechanisms of drug resistance in this species [6]. This
high resistance leads to several therapeutic complica-
tions and is associated with treatment failure and death.
The development of a vaccine against P. aeruginosa for
active and/or passive immunization is therefore neces-
sary as another approach to therapy.
Despite high numbers of patients who may develop P.
aeruginosa infections and the threat of antibiotic treat-
ment failure due to bacterial resistance, there is surpris-
ingly no P. aeruginosa vaccine currently available on the
market, although many attempts have been made in the
past. A number of different vaccines and several mono-
clonal antibodies have been developed in the last dec-
ades for active and passive vaccination against P.
aeruginosa [7]. Different antigens of P. aeruginosa, such
as the outer membrane proteins (Oprs), LPS, toxins, pili
and flagella, have been investigated as possible targets
for the development of vaccines. Vaccination with outer
membrane protein antigens has been shown to be effica-
cious against P. aeruginosa infection in a number of
* Correspondence: fabio.rossano@unina.it
1Department of Cellular and Molecular Biology and Pathology “L. Califano”,
University of Naples “Federico II”, Via S. Pansini 5, 80131 Naples, Italy
Peluso et al. BMC Microbiology 2010, 10:9
http://www.biomedcentral.com/1471-2180/10/9
© 2010 Peluso et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.studies using killed whole cells [8], purified outer mem-
brane preparations [9], isolated outer membrane pro-
teins [10-12], protein fusions, or synthetic peptides
representing protective epitopes [13]. The P. aeruginosa
major constitutive porin protein, OprF, which has pre-
viously been shown to be antigenic [10,14] and has high
homology among Pseudomonas strains [11,15], was also
chosen as a vaccine target [16]. This protein has been
shown to provide protection in a mouse model of sys-
temic infection [10], a mouse burn infection model, and
rodent models of acute [17] and chronic lung infection
[11].
While many of experimental vaccines and monoclonal
antibodies have been tested in preclinical trials, few have
reached clinical phases because it is difficult to study
cystic fibrosis patients, in which improved antibiotic
therapy impaired a proper evaluation of the vaccine’s
efficacies [7] and none of these vaccines has obtained
market authorization [8]. New promising perspectives
for the development of vaccination strategies against
various types of pathogens are the use of antigen-pulsed
dendritic cells (DCs) as biological immunizing agents
[18-20].
DCs are specialized antigen-presenting cells that play a
dual role in inducing adaptive immune responses to for-
eign antigens and in maintaining T cell tolerance to self
[21]. Although there are still numerous controversial
and unresolved issues surrounding DC-mediated
immune responses against pathogens [22], the role of
DCs in immunity to P. aeruginosa is undisputed [23].
Moreover, DCs have a central role in developing new
vaccine strategies due to some prominent features, such
as location, antigen handling, maturation, and subsets
[21,24].
We designed and tested the efficacy of OprF-pulsed
DCs for a vaccine based upon adoptive transfer in mice
with P. aeruginosa infection. To overcome the problem
of quantity and purity related to the purification of
OprF from bacterial outer membrane, we resorted to
recombinant OprF, C-terminal part of which carries an
important protective epitope [25]. The results reported
in this paper demonstrate the ability of mouse DCs
pulsed with purified or recombinant OprF to protect
mice against P. aeruginosa infection and inflammation.
Results and Discussion
Native or recombinant OprF activate DCs in vitro
To assess the immunogenic capacity of native or recom-
binant OprF, we evaluated levels of costimulatory anti-
gen expression (CD80 and CD86) and cytokine
production of DCs pulsed with different concentrations
(2 and 10 μg) of either native or recombinant OprF or
LPS, as a positive control. Similar to LPS, both porins
increased CD86 and CD80 expression in a dose-
dependent manner (Fig. 1A). Class II MHC antigen
expression was also significantly increased by 10 μg/ml
of both porins (from 19 to 47, 43 and 45% of positive
cell in unpulsed DCs versus LPS-, n-OprF- or His-OprF-
pulsed DCs). In terms of cytokine production, both por-
ins induced equivalent levels of TNF-a production,
which was partially Toll like receptor (TLR)4-dependent
for the native porin but almost totally TLR4-indepen-
dent for the recombinant porin (Fig. 1B), a finding con-
firming the absence of LPS contamination in the His-
OprF preparation. Interestingly, levels of IL-12p70 pro-
duction were higher and those of IL-10 and IL-6 lower
in DCs stimulated with the recombinant porin as com-
pared to the native porin (Fig. 1C), a finding suggesting
the superior capacity of the recombinant OprF to acti-
vate DCs for Th1 priming.
OprF-pulsed DCs protect mice from PAO1 infection
Based on these results, we assessed the capacity of DCs
pulsed with either porin to immunize mice against P.
aeruginosa lung infection. To this purpose, porin-pulsed
DCs were administered to mice a week before the intra-
nasal infection with the PAO1 strain. Mice were moni-
tored for bacterial growth, lung inflammatory pathology
and cytokine production locally in the lung (at 4 days
after the infection) or in the thoracic lymph nodes
(TLNs, at 7 days after infection). The results (Fig. 2A)
showed that the adoptive transfer of DCs pulsed with n-
OprF exerted significant protection in terms of reduced
bacterial growth, both at 4 and 7 days after the infec-
tion. No effects on bacterial clearance was observed
upon adoptive transfer of unpulsed DCs.
Interestingly, an even higher bacterial clearance was
observed upon adoptive transfer of DCs pulsed with
His-OprF, being the bacterial growth dramatically
reduced as early as 4 days after the infection.
As a similar degree of protection in terms of reduced
bacterial clearance was also observed upon infecting the
mice intratracheally (data not shown), we concluded
that the lower airways of the lung are the sites of both
the induction and expression phase of the DC-induced
resistance against P. aeruginosa.
To correlate vaccine-induced resistance with pattern
of inflammatory and Th cytokine production in mice
with infection, levels of pro-inflammatory (TNF-a/IL-
12p70) or anti-inflammatory (IL-10) cytokines were
measured in the lung homogenates and those of Th1
(IFN-g) or Th2 (IL-4/IL-10) in antigen-stimulated TLNs.
The results show that levels of TNF-a were significantly
r e d u c e dw h e r e a st h o s eo fI L - 1 2 p 7 0a n dI L - 1 0b o t h
increased in vaccinated mice (Fig. 2B). In the TLNs, the
levels of Th1/IFN-g production were increased in mice
vaccinated with DCs pulsed with either porin, while
those of Th2/IL-4 were decreased, particularly with the
His-OprF-pulsed DCs. Interestingly, mice vaccinated
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of IL-10 production. As in cystic fibrosis (CF) patients
priming of the cellular immune system towards a Th1-
like pattern seems to be of potential advantage [26],
while pulmonary Th2 responses are seen in CF patients
with Pseudomonas p n e u m o n i a[ 2 7 ] ,o u rd a t as u g g e s t
that vaccine-induced resistance correlates with the acti-
vation of protective Th1 cell responses and decrease of
non-protective Th2 responses.
To correlate these findings with levels of pulmonary
inflammation, we evaluated sections of lungs from unin-
fected, infected or vaccinated mice for inflammatory cell
recruitment and lung injury (Fig 3 and 4). In the Fig. 4A
and 4B haematoxylin-eosin sections from mice infected
with PAO1 strain show the presence of lung parench-
yma, with an evident inflammatory infiltrate, mainly
constituted of polymorphous granulocytes, involving
small bronchi, bronchioles, and alveoli, up to the forma-
tion of abscesses with tissue necrosis.
In contrast, inflammatory cell recruitment was greatly
reduced in the lungs of mice vaccinated with n-OrpF-
pulsed DCs (Fig 4C and 4D) or His-OprF-pulsed DCs
(Fig. 4E and 4F).
OprF-pulsed DCs protect mice from infection with the
clinical isolate
Because chronic lung infections with P. aeruginosa are
associated with the diversification of the persisting clone
into different morphotypes [28] and P. aeruginosa iso-
lates from chronic CF lung infections are phenotypically
quite distinct from those causing acute infections in
other settings [29], we assessed whether the vaccinating
potential of porin-pulsed DCs would extend to a mucoid
strain isolated from CF patients. To this purpose, mice
were treated, infected and evaluated for microbiological
and immunological parameters as above. Figures 5A, B
and 6 show the cumulative results of these experiments.
Consistent with the high virulence of mucoid bacterial
strains [30], the clearance of the bacteria from the lung
Figure 1 Activation of murine dendritic cells by OprF. Purified splenic dendritic cells (DCs) were pulsed with LPS (10 μg/ml), native (n) or
recombinant (His) OprF at different concentrations for 18 hrs before the assessment of costimulatory molecule expression (A) and cytokine
production (B and C). FACS analysis was done by staining with FITC and PE-conjugated mAbs to costimulatory molecules. Number represent
percent of positive cells. Cytokine levels were determined in the culture supernatants by cytokine-specific ELISA. * Indicates P < .05 (cytokine
production by LPS- or porin-pulsed versus unpulsed (-) DCs). ** Indicate P < .05 (cytokine production by n-OprF-pulsed tlr4
-/- DCs versus n-OprF-
pulsed WT DCs only and His-OprF-pulsed DCs versus n-OprF-pulsed DCs).
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Page 3 of 11Figure 2 OprF-pulsed DCs protect mice from infection with the PAO1 strain. Splenic 10
5 dendritic cells (DCs), either unpulsed (-) or pulsed
as in legend to figure 1, were administered into recipient mice intraperitoneally a week before the intranasal injection of 3 × 10
7 P. aeruginosa
PAO1 strain. (A) Resistance to infection was assessed in terms of CFU at different days after the infection and (B) cytokine production in lung
homogenates and culture supernatants of total cells from TLNs stimulated with plate bound anti-CD3e (2 μg/ml) and anti-CD28 (2 μg/ml) for 72
hours. Results are expressed as mean ± SE. * Indicates P < .05, mice receiving pulsed versus unpulsed (-) DCs. In C, - and + alone indicate
uninfected and infected mice, respectively.
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colonization at 7 days after infection (Fig. 5A). Never-
theless, treatment with either type of pulsed DCs signifi-
cantly reduced bacterial growth, although to a lesser
extent compared to PAO1-infected mice (Fig. 5A).
Although levels of Th1 cytokines (IL-12p70/IFN-g)w e r e
significantly higher and those of Th2/IL-4 lower in DCs-
vaccinated mice as compared to untreated mice, levels
of TNF-a were not significantly decreased in DCs-trea-
ted versus untreated mice. Moreover, although increased
if compared to untreated mice, levels of IL-10 were not
as high as those induced in PAO1-infected mice (Fig.
5B). Lung inflammatory cell recruitment was signifi-
cantly reduced by treatment with either type of pulsed
DCs, although to a lesser extent compared to PAO1-
infected mice (Fig. 6). Together, our data indicate that
porin-pulsed DCs may induce immune protection
against pulmonary infection by P. aeruginosa with a sig-
nificant reduction of inflammation.
It is believed that the initial site of colonization by P.
aeruginosa is localized to the upper respiratory epithe-
lium; therefore, inducing mucosal immunity to this
pathogen appears to be an ideal strategy for the preven-
tion of infection. Previous studies suggested that sys-
temic immunity, from either oral vaccination [8] or i.p.
vaccination [31] with P. aeruginosa vaccine constructs,
was as effective as mucosal delivery of the vaccine in a
mucosal challenge.
We found here that peripheral delivery of porin-
pulsed DCs also resulted in active immunization against
Pseudomonas pneumonia. Protection occurred against
pneumonia induced by either intranasal or intratracheal
delivery of the bacteria, a finding consistent with the
above-mentioned studies and confirming that peripheral
immunization may result in mucosal and parenchymal
protection at distal sites.
Protection was associated with increased bacterial
clearance, decreased inflammatory pathology and the
occurrence of Th1 immunity in the draining lymph
nodes. Although antibodies have a crucial role in pro-
tection against P. aeruginosa infection, cell-mediated
immunity is also important in the clearance of the bac-
terium. The observation that the occurrence of a protec-
tive Th1 reactivity coexisted with the detection of
significant levels of IL-10 is intriguing. It is known that
high levels of IL-10 are associated with protection in
patients with CF and IL-10 is required for the induction
of regulatory T cells dampening inflammation in infec-
tions [32]. Whether IL-10 produced in DCs-vaccinated
mice may serve to support the growth of regulatory T
cells preventing prolonged inflammation is an attractive
working hypothesis.
Conclusions
There is surprisingly no P. aeruginosa vaccine currently
available on the market, although many attempts have
been made in the past. This raises the question as to
whether P. aeruginosa is an antigenically variable micro-
organism that can escape immune recognition and/or
induce immunological non-responsiveness as is seen
with other bacteria such as Borrelia, Bordetella or Neis-
seria. Because the organism has the ability to undergo
phenotypic variation due to changing environmental
conditions such as in the airways of CF patients [29],
the highly conserved antigens such as Oprs represent
ideal candidates for vaccines. However, despite highly
efficient technologies to express proteins and to purify
protein and carbohydrate antigens in high yields under
good manufacturing practices standards, the lack of a
protective P. aeruginosa vaccine is a reality. Our study
would suggest that the use of porin-pulsed DCs may
represent a possible candidate vaccine against
Figure 3 Lung sections from uninfected mice. Lung sections were hematoxylin-eosin stained. A - magnification ×10. B - magnification ×40.
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Page 5 of 11Figure 4 Lung sections of mice vaccinated with OprF-pulsed DCs and infected with PAO1 strain. Histopathology at 7 days after infection.
Lung sections A-B from infected mice show the involvement of bronchioles and of the alveolar space by an inflammatory infiltrate
predominantly consisting of neutrophils filling most of bronchioles (red arrow: bronchial epithelium; blue arrow: neutrophilic infiltrate); the lungs
sections from mice vaccinated with n-OprF-pulsed DCs (C-D) and His-OprF-pulsed DCs (E-F) show a great reduction of inflammatory cell
recruitment. Lung sections were hematoxylin-eosin stained. A-C-E magnification ×10. B-D-F magnification ×40.
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against both the conventional PAO1 strain and the
more virulent mucoid strain, this finding highlights the
potential of DCs to overcome the mucin-dependent
negative regulation of immune responses to P. aerugi-
nosa [33].
Confirming the efficacy of several tested Opr vaccine
preparations in generating protection against different P.
aeruginosa challenges in preclinical studies [9], OprF-
pulsed DCs not only induced Th1 resistance to the
infection but also ameliorate inflammatory pathology.
This finding is of relevance considering the contribution
of a self-sustaining cycle of airway obstruction, infection,
and inflammation to lung disease in CF [34]. CF lung
disease is characterized by neutrophilic airway inflam-
mation, increased expression of proinflammatory cyto-
kines, and infection by a narrow repertoire of bacterial
pathogens, with P. aeruginosa and Burkholderia cepacia
complex being the most clinically significant pathogens.
Current therapy for CF lung disease relies on antibiotics
to treat bacterial infection combined with airway clear-
ance strategies to mobilize viscid secretions. However,
Figure 5 OprF-pulsed DCs protect mice from infection with the clinical isolate. Splenic DCs were pulsed and administered as in legend to
figure 1. Mice were infected intranasally with 3 × 10
7 P. aeruginosa mucoid strain. (A) Resistance to infection and (B) cytokine production in lung
homogenates and culture supernatants of TLNs were assessed as in legend to Figure 2. * Indicates P < .05 (mice receiving pulsed versus
unpulsed (-) DCs). In C - and + alone indicate uninfected and infected mice, respectively.
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Page 7 of 11Figure 6 Lung sections of mice vaccinated with OprF-pulsed DCs and infected with clinical isolate. Lung sections A-B representing
histologic pictures of pneumonia similar to those described in fig. 4 are shown (red arrow: bronchial epithelium; blue arrow: neutrophilic
infiltrate). Lung sections from mice vaccinated with n-OprF-pulsed DCs (C-D) and His-OprF-pulsed DCs (E-F) show a lung in which inflammatory
cell recruitment was greatly reduced. Lung sections were hematoxylin-eosin stained. A-C-E magnification ×10. B-D-F magnification ×40.
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cial for patients with CF [34], especially for younger
patients with mild disease. Recent data indicate that
TLR4- and flagellin-induced signals mediate most of the
acute inflammatory response to Pseudomonas [35]. The
fact that DCs activation by recombinant OprF occurred
independently of TLR4 would suggest that avoiding the
damaging inflammatory pathway to the bacterium may
be of benefit in vaccine-induced protection. Overall, our
study points to the successful combination of recombi-
nant porins and DCs for vaccine-induced protection in
the relative absence of innate danger signals. However,
much needs to be done to work out principles that gov-
ern the regulation of the human immune system in vivo
in patients with pneumonia, including the immunobiol-
ogy of DCs in immune resistance to Pseudomonas.
Methods
Bacterial strains and growth conditions
The strain of P. aeruginosa PAO1 was purchased from
the American Type Culture Collection, Rockville, MD.
(ATCC, BAA-47). A clinical strain, isolated from a CF
patient, was obtained from the Diagnostic Unit of
Microbiology of the University of Naples “Federico II”.
The bacteria were grown on 2% proteose peptone (PP2)
and 0.5% NaCl. Overnight cultures grown under contin-
uous shaking at 37°C, were diluted 10- to 20- fold into
fresh medium at 37°C to an optical density of 0.6-0.8
(600 nm).
Mice
Female C57BL/6 mice, 8-10 wk old, were purchased
from Charles River (Calco, Italy). Homozygous Tlr4
-/-
mice on a C57BL/6 background were bred under speci-
fic pathogen-free conditions at the Animal Facility of
Perugia University, Perugia, Italy [36]. Experiments were
performed according to the Italian Approved Animal
Welfare Assurance A-3143-01.
Purification of native porin F (OprF) from P. aeruginosa
The porin was isolated and purified from PAO1 bacter-
ial strain following the method described by Hancock R.
E.W (Hancock Laboratory Methods, Department of
Microbiology and Immunology, University of British
Columbia, British Columbia, Canada, http://www.cmdr.
ubc.ca/bobh/methods/PORINPURIFICATION.html).
Briefly, bacteria were grown overnight at 37°C; fresh
inoculum was added the day after and grown until loga-
rithmic phase. Bacteria were harvested and resuspended
in 20% sucrose, 10 mM Tris-HCl, pH8, in the presence
of DNaseI (50 μg/ml). The cells were broken by a
French Press at 15,000 psi three times and then soni-
cated (power 35/5 cycles/30 seconds). The lysate was
applied to the top of a 2-step sucrose gradient (72% and
52%) and centrifuged at 58,357 g overnight at 4°C. The
day after, the outer membranes were collected and
washed by centrifugation at 142,743 g/1 h/4°C. The pro-
teins of the outer membrane were purified by solubiliza-
tion with 2% Triton X-100, 20 mM TrisHCl, pH8, and
t h e nw i t h2 %T r i t o nX - 1 0 0 ,2 0m MT r i s H C l ,p H 8 ,1 0
mM EDTA, to remove all remaining bound LPS and
phospholipids. At each passage, the pellet was sonicated
at a probe intensity of 35/30 sec and then centrifuged at
145,424 g/1 hr/4°C. The fractions, solubilized with 2%
Triton X-100, 20 mM TrisHCl, pH8, were centrifuged
145,424 g/1 hr/4°C and the supernatant was loaded on a
DEAE-Sephacel column, equilibrated with 0.2% Triton
X-100, 20 mM TrisHCl, pH8, 10 mM EDTA (column
buffer). OprF was eluted using a 0.1 M - 0.3 M NaCl
linear gradient. The porin preparation was run on a gel-
filtration column (Amersham Biosciences), (column buf-
fer was: 0.25% SDS, 10 mM NaCl, 5 mM EDTA, 0.05%
b-mercaptoethanol). The purity of OprF was checked by
SDS-PAGE followed by Western blotting with the MA7-
7 at high specificity monoclonal antibody [37] (kindly
gifted by Dr R.E.W Hancock). Limulus amoebocyte
lysate (LAL) assay [38] was performed to evaluate LPS
contamination (100 pg/μg porins) in native porin
preparation.
Preparation of recombinant OprF (His-OprF)
Genomic DNA was extracted from P. aeruginosa PAO1
strain and the oprF sequence was amplified by PCR with
specific primers: 5’-CGCGGATCCAAACTGAAGAA
CACCTTAGGCGTTGTC-3’ (Fw) and 5’-CCCAAGC
TTTTACTTGGCTTCGGCTTCTACTTCGGC-3’ (Rev).
The oprF gene fragment was cloned (BamHI and Hind
III) into the pET28a expression vector (Novagen), that
has an His6 affinity tag at the 5’ end of the polylinker
that functions as a high affinity nickel-binding domain
in the translated protein. To be sure that all the OprF
nucleotide sequence was completely cloned, the plasmid
was sequenced by automated sequencing using Sanger’s
method and the sequence was compared with the
sequence reported in GenBank. The Qiagen expression
host cells, E. coli BL21, were made competent and trans-
formed with the resulting plasmid pET28a-oprF. Expres-
sion of recombinant OprF (His-OprF) was induced by
the addition of isopropyl-b-D-thiogalactoside (IPTG)
(Sigma; 1 mM final concentration). E. coli BL21 cells
were harvested by centrifugation and His-OprF was pur-
ified by denaturing conditions on a nickel-nitrilotriacetic
acid affinity chromatography gel matrix (Sigma Aldrich).
The recombinant protein purification was performed by
denaturing conditions in four steps, as follows: solubili-
zation with 8 M urea, 0.1 M NaH2PO4, 0.01 M TrisHCl,
pH8; washing with 8 M urea, 0.1 M NaH2PO4,0 . 0 1M
TrisHCl, pH 6.3 and 8 M urea, 0.1 M NaH2PO4, 0.01 M
TrisHCl, pH 5.9; eluation of the interested protein with
8 M urea, 0.1 M NaH2PO4, 0.01 M TrisHCl, pH 4.5.
Pure His-OprF was solubilized in 0.25% SDS, 5 mM
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gels stained with silver nitrate [39] and quantified by
Limulus amoebocyte lysate (LAL) assay [38]. Recombi-
nant OprF preparation was completely free from LPS
contamination. Moreover, the purity of OprF was
checked by SDS-PAGE, followed by Western blotting
using MA7-7 [37] an high specific monoclonal antibody
(kindly gifted by Dr R.E.W Hancock).
Mice infection with P. aeruginosa
C57/BL6 mice were intranasally infected with the non
lethal dose of 3 × 10
7 colony forming units (CFU) of P.
aeruginosa PAO1 strain or the clinically isolated strain,
as from preliminary experiments. At day 4 and day 7 of
infection, mice were sacrificed and lung tissues were
homogenized in PBS buffer containing soybean trypsin
inhibitor. For the bacterial counts, 50 μl dilutions of the
homogenate were plated on trypticase soy agar plates
and then incubated for 24 hrs at 37°C. CFU, quantified
by serial plating on trypticase soy agar plates, were
determined in the lung at 4 or 7 days after infection.
The results (means ± standard errors) are expressed as
CFU/organ. The remaining homogenate was centrifuged
at 16,060 g/30 min/4°C and the supernatant was stored
at -80°C for cytokine determination.
Histology
Lungs were excised en bloc and inflation fixed in 4%
paraformaldehyde in PBS. The lungs were then
embedded in paraffin, and sections were cut and stained
with hematoxylin and eosin using standard techniques.
Isolation of DCs
DCs were purified from spleens by magnetic-activated
sorting using CD11c MicroBeads and MidiMacs (Milte-
nyi Biotec), in the presence of EDTA to disrupt DCs-T
cell complexes [36]. Cells were >99% CD11c
+, < 0.1%
CD3
+, and appeared to consist of 90-95% CD8
-, 5-10%
CD8
+, and 1-5% B220
+ cells.
Antigen pulsing of DCs and mice immunization
DCs were pulsed for 2 hrs at 37°C with native OprF or
with recombinant His-OprF (10 μg/1 × 10
6 cells). Pulsed
DCs (5 × 10
5) were extensively washed before being
administered intraperitoneally a week before the intrana-
sal infection with either strain of P. aeruginosa. Aliquots
of DCs were assessed for cytokine production and costi-
mulatory antigen expression after 18 hrs of culture.
Positive controls included DCs stimulated with 10 μg/
ml ultra-pure lipopolysaccharide (LPS) from Salmonella
minnesota Re 595 (Labogen S.r.l., Rho, Milan, Italy).
Cytokine assays
The cytokine levels in culture supernatants of pulsed-
DCs, in lung homogenates (at 4 days after infection) or
culture supernatants from thoracic lymph nodes (TLNs,
at 7 days after infection) were measured by ELISA
(R&D Systems, Inc., Space Import-Export srl, Milan,
Italy). The detection limits (pg/ml) of the assays were
<10 for IFN-g,< 3 2f o rT N F - a <3 for IL-10, <16 for IL-
12p70 and <7 for IL-6.
Flow cytometry
Staining was done as described [36]. For double staining,
DCs were sequentially reacted with saturating amounts
of FITC-conjugated anti-CD80 and PE-conjugated anti-
CD86 mAb from BD Pharmingen (CD80 and CD86).
Cells were analyzed with a FACScan flow cytofluori-
meter (Becton Dickinson) equipped with CELLQuest™
software. Control staining of cells with irrelevant Ab
was used to obtain background fluorescence values.
Data are expressed as a percentage of positive cells over
total cells analyzed. Flow cytometry was used to deter-
mine the purity of isolated cells.
Statistical analysis
Data were analyzed on PC using InStat version 2.01 and
GraphPad Prism version 4.0 statistical packages (Graph-
Pad Software). The double-tailed Student’s t test was
used to compare the significance of differences between
groups. A value of P < 0.05 was considered significant.
The data reported are either from one representative
experiment out of three independent experiments
(FACS analysis) or pooled from three to five experi-
ments, otherwise. The in vivog r o u p sc o n s i s t e do f6 - 8
mice/group.
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